Risk Of Developing Liver Cancer After HCV Treatment

Tuesday, May 5, 2015

JAMA Author Interview: Daclatasvir, Asunaprevir, and Beclabuvir for HCV Genotype 1


JAMA


Original Investigations | May 5, 2015

Oral Antiviral Treatment of Hepatitis C Genotype 1 Infection

Author Interview @ JAMA - Daclatasvir, Asunaprevir, and Beclabuvir for HCV Infection With CirrhosisThese cohort studies describe outcomes for HCV genotype-1 infected patients with and without cirrhosis who were treated with an all-oral antiviral regimen.



Full Text Available @ NATAP
Editorial: Continued Progress Against Hepatitis C Infection

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis 

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection 

JAMA
Abstract Free - Full content is available to subscribers only

No comments:

Post a Comment